Pharma BD Deal Intelligence
A bust: Boehringer paid up to EUR 1.18B for NBE-Therapeutics and lead asset NBE-002, an anti-ROR1 ADC for triple-negative breast cancer, but the Phase 1/2 trial was terminated for End of Program having enrolled only 12 of a planned ~100 patients.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →ROR1 is highly expressed on the surface of triple-negative breast cancer cells but minimally expressed on normal adult tissues, making it a promising candidate…
Boehringer Ingelheim is paying up to EUR 1.18 billion ($1.4 billion) to acquire Swiss biotech NBE-Therapeutics, snagging an immune-stimulatory ADC platform and…
In 2021, the American Cancer Society estimates 281,550 new cases of invasive breast cancer and 43,600 breast cancer deaths in U.S. women. Triple-negative…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Boehringer Ingelheim signed a binding agreement to acquire Swiss biotech NBE-Therapeutics for EUR 1.18B (~$1.4B); the deal closed March 4, 2021. It brought NBE's immune-stimulatory ADC (iADC) platform plus lead asset NBE-002 (zinitevatug), an anti-ROR1 ADC then in Phase 1 for TNBC and solid tumors, complementing Boehringer's antigen-discovery and T-cell-engager capabilities and entering the increasingly competitive ROR1 ADC race alongside Merck/VelosBio. Post-close, the program did not pan out: the NBE-002 Phase 1/2 trial (NCT04441099) was terminated for "End of Program" with a primary completion date of August 14, 2023, having enrolled only 12 of a planned ~100 patients. The acquisition's central clinical asset was thus discontinued, leaving the iADC platform as the residual value of the transaction.
Assessment window: 5yr post-close.
35K US cases/yr · $1.5B US TNBC drug market 2020 (USD MM) · 50 % TNBC tumors expressing ROR1 (Cui et al., Cancer Res 2013)
Triple-negative breast cancer accounts for approximately 10-15% of all breast cancer diagnoses, translating to roughly 30,000-40,000 new US cases annually given the American Cancer Society's 2021 estimate of 281,550 new invasive female breast cancer cases. TNBC is defined by absent expression of estrogen receptor, progesterone receptor, and HER2, eliminating endocrine therapy and HER2-directed antibody-drug conjugates from the treatment toolkit. TNBC disproportionately affects younger women (median age 53 vs 60 for hormone-receptor-positive disease), Black women (incidence rate ratio ~1.9), and BRCA1 mutation carriers (60-80% of BRCA1 breast cancers are TNBC). Five-year survival for metastatic TNBC remains under 15%. Standard front-line metastatic therapy is chemotherapy (taxanes, platinum, anthracyclines, capecitabine, eribulin) with PD-L1 inhibitor add-on (Tecentriq+nab-paclitaxel approved 2019, withdrawn 2021; Keytruda+chemotherapy approved Nov 2020 for PD-L1 CPS≥10). ROR1 (receptor tyrosine kinase-like orphan receptor 1) is an oncoembryonic antigen broadly expressed across TNBC (~50% prevalence), mantle cell lymphoma, CLL, and several solid tumors, with minimal expression on normal adult tissues — making it an attractive ADC target. NBE-002 is an anti-ROR1 antibody conjugated to NBE's proprietary anthracycline payload PNU-159682, designed to deliver immunogenic cell death and recruit tumor immunity in addition to direct cytotoxicity.
At deal date (Dec 2020) the ADC and ROR1 competitive landscape was rapidly heating. The most direct ROR1 competitor was VelosBio's zilovertamab vedotin (VLS-101, anti-ROR1 MMAE ADC), which Merck acquired for $2.75B just 35 days earlier (Nov 5, 2020) — making the NBE-Boehringer transaction the second major ROR1 ADC consolidation in five weeks. Other ROR1 programs included Oncternal Therapeutics' cirmtuzumab (anti-ROR1 mAb, Phase 2 in CLL/MCL with ibrutinib) and BeiGene/MapKure's BGB-A445 (preclinical). The broader ADC landscape in TNBC and solid tumors at deal date: Trodelvy (sacituzumab govitecan, anti-Trop-2 SN-38 ADC, Immunomedics — Gilead acquisition closed Sep 2020 for $21B; FDA accelerated approval Apr 2020 for mTNBC), Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo — HER2-low TNBC trials ongoing, DESTINY-Breast04 readout in 2022), Kadcyla (T-DM1, Roche), Padcev (enfortumab vedotin, Astellas/Seagen — urothelial), Polivy (polatuzumab vedotin, Roche — DLBCL), Adcetris (brentuximab vedotin, Seagen — Hodgkin/T-cell). Adjacent IO+chemo regimens in mTNBC: Keytruda + chemo (KEYNOTE-355, approved Nov 2020), Tecentriq + nab-paclitaxel (IMpassion130, withdrawn Aug 2021). PARP inhibitors in BRCA-mutated TNBC: Lynparza (olaparib), Talzenna (talazoparib). The iADC platform's anthracycline payload differentiates from MMAE/MMAF auristatins and DXd topoisomerase-I inhibitors that dominate the field, with the immune-stimulatory dimension positioning NBE-002 for combination with checkpoint inhibitors.
The NBE-002 (zinitevatug) anti-ROR1 ADC Phase 1/2 trial (NCT04441099) was terminated for "End of Program," enrolling only 12 of ~100 planned patients (primary completion 2023-08-14). The acquisition's central clinical asset was discontinued.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG (this deal) | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2020 deals · Boehringer Ingelheim GmbH deals · Oncology deals